Comparative Pharmacology
Head-to-head clinical analysis: CLAFORAN versus SUPRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLAFORAN versus SUPRAX.
CLAFORAN vs SUPRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime is a bactericidal cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1-2 g IV/IM every 8 hours. Maximum dose: 12 g/day in divided doses.
400 mg orally once daily or 200 mg orally every 12 hours.
None Documented
None Documented
0.8-1.4 hours in normal renal function (prolonged to 11-30 hours in severe renal impairment, CrCl <10 mL/min). No clinically relevant accumulation with standard dosing in renal impairment with dose adjustment.
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 11-15 hours in severe renal impairment (CrCl <20 mL/min).
Primarily renal (80-90% unchanged in urine via glomerular filtration and tubular secretion); biliary/fecal <10%.
Renal: 50-55% unchanged in urine; biliary/fecal: 10-20% (biliary excretion); remainder metabolized or excreted via feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic